Spyryx Biosciences Company
Spyryx Biosciences develops a next-generation therapeutics for obstructive lung diseases.
Investors Number:
3
Industry:
PharmTech
Technology:
Biologics
Total Funding:
$18.2M
Last Funding Type:
Series A
Investor Type:
For Profit
Headquarters:
Durham, North Carolina, United States
Funding Status:
Early Stage Venture
Employee Number:
11-50
Estimated Revenue:
$1M to $10M
Founded Date:
2013